Oxidative stress, Sperm DNA fragmentation, and Varicocele: From mechanisms to precision management in male infertility

Varicocele remains the most prevalent correctable finding in male infertility, yet its clinical interpretation is increasingly challenged by the limited explanatory power of conventional semen analysis. Emerging evidence positions varicocele as a biologically active lesion characterized by redox imbalance and downstream genomic instability, rather than a purely anatomical venous disorder. Oxidative stress (OS) and sperm DNA fragmentation (SDF) have therefore gained translational relevance as mechanistic intermediates linking varicocele to impaired fertilization, defective embryogenesis, recurrent pregnancy loss, and suboptimal assisted reproductive outcomes. Mechanistically, varicocele induces a convergence of hyperthermia, venous stasis, hypoxia-like stress, inflammation, and mitochondrial dysfunction, culminating in excessive reactive oxygen species (ROS) generation and failure of redox homeostasis. Given the intrinsic vulnerability of spermatozoa, characterized by limited antioxidant defenses and minimal DNA repair capacity, this oxidative milieu promotes lipid peroxidation, chromatin destabilization, and DNA strand breaks. Clinical syntheses consistently demonstrate elevated SDF in men with varicocele and indicate that varicocelectomy can reduce oxidative damage markers and SDF in selected patients, supporting a biologically responsive axis rather than incidental association. Despite these advances, critical uncertainties persist regarding assay standardization, clinically actionable SDF thresholds, and the extent to which biomarker improvement translates into live birth benefit. Current guidelines recommend selectively using SDF in clinical decisions for unexplained infertility, recurrent pregnancy loss, and ART failure, shifting toward phenotype-driven care. The OS-SDF-varicocele axis moves male infertility from descriptive approaches to mechanism-based precision treatment. Progress relies on molecular phenotyping, validating outcome-linked biomarkers, and redefining ‘idiopathic’ infertility into biologically distinct groups.